United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Click ...

United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn ...

The conference represents a unique collaboration between the Prader-Willi Syndrome Association | USA (PWSA | USA), the ...

Fintel reports that on June 2, 2025, Cantor Fitzgerald initiated coverage of United Therapeutics (NasdaqGS:UTHR) with a ...

It has been about a month since the last earnings report for United Therapeutics (UTHR). Shares have added about 9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

United Therapeutics UTHR shares soared 3.5% in the last trading session to close at $286.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

In the last three months, 7 analysts have published ratings on United Therapeutics UTHR, offering a diverse range of perspectives from bullish to bearish. The following table summarizes their ...

One great example is United Therapeutics Corporation (NASDAQ:UTHR) which saw its share price drive 151% higher over five years. We note the stock price is up 1.9% in the last seven days.

On Wednesday, Leerink Partners analysts reaffirmed their Outperform rating for United Therapeutics Corp . (NASDAQ:UTHR) and maintained a price target of $418.00. This decision comes as the company ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.